Stocks · News reference
Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
United Therapeutics Corporation has received FDA clearance to proceed with a Phase 1 clinical trial for its treprostinil-iloprost combination therapy for pulmonary arterial hypertension.
RBC Capital Markets has lowered its price target for United Therapeutics Corporation from $708 to $697 while maintaining an Outperform rating.